Barbara Burtness, MD, Named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital
Barbara Burtness, MD, Professor of Medicine (Medical Oncology), has been named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research for Yale Cancer Center.
The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss
Oropharyngeal squamous cell carcinoma (OPSCC) accounts for over half of all head and neck cancers. Since the 1970s, OPSCC has shifted from an environmentally triggered to virally mediated disease due to a sharp rise in human papillomavirus (HPV)-related SCC.Source: National Library of Medicine
Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer
Head and neck squamous cell carcinoma (HNSCC) is a frequently devastating cancer that affects more than a half million people annually worldwide. In a paper recently published in AACR Journals, Dr. Barbara Burtness reveals the relation of the interaction of TP53 and CDKN2A mutations with elevated tumor mutation burden in HNSCC.Source: AACR Journals
Manju Prasad, MD, MBBS, on Head and Neck Cancer Awareness Month
In recognition of Head and Neck Cancer Awareness Month, Manju Prasad, MD, MBBS, Professor of Pathology; Director, Endocrine Head and Neck Pathology Fellowship Program; Director, Endocrine Head and Neck Pathology, provides her insight.
Reduced Radiation Dose After Surgery May Improve Survival Rates in HPV-Related Throat Cancer
Transoral robotic surgery followed by low-dose radiation may reduce treatment intensity and improve long-term quality of life compared to usual care, which consists of high-dose radiation and chemotherapy, in patients with HPV-associated throat cancer, recent study findings demonstrate.Source: Cure Today
Yale Cancer Center Researchers Identify New Role for Immune-Boosting Protein “STING” in Treatment of Head and Neck Cancer
In a study by Yale Cancer Center, researchers report on the discovery of a new role for STimulator of INterferon Genes or STING. STING has traditionally been implicated in the immune response to DNA damage, however, in this study, the focus is on STING’s role in the tumor DNA damage response.
Transformative Treatments for Head and Neck Cancers
New life-changing advances in treatment for head and neck cancers, as well as the FDA’s approval of pembrolizumab, stem from research done by physician-scientists at Yale, particularly through the leadership of Barbara A. Burtness, MD. Dr. Burtness directed a large, international, randomized phase III clinical trial whose results persuaded the FDA to approve the new treatment.